Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
August 02 2024 - 4:05PM
Verve Therapeutics, a clinical-stage company developing a new class
of genetic medicines for cardiovascular disease, today announced
that on July 31, 2024, the company granted equity awards to five
new employees, pursuant to the company’s 2024 Inducement Stock
Incentive Plan, as an inducement material to each new employee
entering into employment with the company in accordance with Nasdaq
Listing Rule 5635(c)(4).
The employees received stock options to purchase an aggregate of
91,200 shares of the company’s common stock and an aggregate of
37,300 restricted stock units (RSUs). The options have an exercise
price of $7.00 per share, which is equal to the closing price of
the company’s common stock on the date of grant. Each option has a
10-year term and will vest over a period of four years, with 25% of
the shares vesting on the one-year anniversary of the grant date
and the remainder vesting in equal monthly installments over the
following three years, subject to each such employee’s continued
service with the company on each such vesting date. The RSUs will
vest in equal annual installments on the first four anniversaries
of October 1, 2024, subject to each such employee’s continued
service with the company on each such vesting date.
About Verve Therapeutics Verve
Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company
developing a new class of genetic medicines for cardiovascular
disease with the potential to transform treatment from chronic
management to single-course gene editing medicines. The company’s
lead programs – VERVE-101, VERVE-102, and VERVE-201 – target genes
that have been extensively validated as targets for lowering
low-density lipoprotein cholesterol (LDL-C), a root cause of
atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and
VERVE-102 are designed to permanently turn off
the PCSK9 gene in the liver and are being developed
initially for heterozygous familial hypercholesterolemia (HeFH) and
ultimately to treat patients with established ASCVD who continue to
be impacted by high LDL-C levels. VERVE-201 is designed to
permanently turn off the ANGPTL3 gene in the liver and is
initially being developed for homozygous familial
hypercholesterolemia (HoFH) and for refractory hypercholesterolemia
where patients still have high LDL-C despite treatment with
maximally-tolerated standard of care therapies. For more
information, please visit www.VerveTx.com.
Investor ContactJen RobinsonVerve Therapeutics,
Inc.jrobinson@vervetx.com
Media ContactAshlea
Kosikowski1ABashlea@1abmedia.com
Verve Therapeutics (NASDAQ:VERV)
Historical Stock Chart
From Sep 2024 to Oct 2024
Verve Therapeutics (NASDAQ:VERV)
Historical Stock Chart
From Oct 2023 to Oct 2024